Praxis Precision Medicines, Inc. PRAX 深 沪
已收盘 02-13 16:00:00 美东时间
318.065
-14.855
-4.46%
华盛通- 最 高335.75
- 今 开332.74
- 成交量 30.58万股
- 最 低 266.51
- 昨 收 332.92
- 总市值 1447.57万
- 52周最高 335.75
- 市盈率 静 --
- 换手率 672.02%
- 52周最低 26.70
- 委 比 -93.33%
- 总股本 4.55万
- 历史最高 335.75
- 量 比 0.82
- 振 幅 20.80%
- 历史最低 0.70
- 每 手 1
- 风险率 99.72%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Praxis Stock Surges On FDA Breakthrough Status For Essential Tremor Drug
Praxis Precision Medicines Inc (NASDAQ: PRAX) stock rose after FDA granted BTD for ulixacaltamide to treat essential tremor.
2025-12-30 01:21
Praxis' Epilepsy Drug Too Good To Continue, FDA Meeting Up Next
Praxis Precision stock rallies on positive EMBOLD results, FDA meeting confirmed, and analyst increases probability of success and peak sales.
2025-12-06 02:10
Crude Oil Moves Higher; Domo Shares Plunge
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gai...
2025-12-06 01:30
Kimberly-Clark, Vertex And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining mor...
2025-11-03 21:14
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines granted 750 RSUs to a new employee under their 2024 Inducement Plan, vesting annually over four years. The RSUs are part of the employee's compensation incentives.
2025-06-04 21:00
Needham Reiterates Buy on Praxis Precision Medicine, Maintains $151 Price Target
Needham analyst Ami Fadia reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $151 price target.
2024-09-05 18:22
Forecasting The Future: 14 Analyst Projections For Praxis Precision Medicine
Analysts' ratings for Praxis Precision Medicine (NASDAQ:PRAX) over the last quarter vary from bullish to bearish, as provided by 14 analysts. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding ...
2024-09-05 05:00
Philip Morris International To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler cut the price target for Asana, Inc. (NYSE:ASAN) from $14 to $12. Piper Sandler analyst Brent Br...
2024-09-04 21:38
Praxis Precision Medicines To Highlight Their Epilepsy Portfolio At The International League Against Epilepsy 15th European Epilepsy Congress With Six Presentations
Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that that it will present pr...
2024-09-04 20:02
Wedbush Adjusts Price Target on Praxis Precision Medicines to $51 From $48, Maintains Neutral Rating
06:17 AM EDT, 09/04/2024 (MT Newswires) -- Praxis Precision Medicines (PRAX) has an average buy rating and a price target range of $51 to $270, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research from major banks and research firms in North Americ...
2024-09-04 18:17
